Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches" is generating significant coverage in the Health category, with 4 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include ConsumerAffairs, YPulse, MDLinx and Bloomberg.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 88d ago.
Quick answers
Why is "Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches" trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (4)
- GLP-1 drugs are changing how teens and young adults treat obesity ConsumerAffairs · 91d ago
- Are Teens and Young Adults Actually Using GLP-1s? YPulse · 91d ago
- The pediatric GLP-1 dilemma at summer camp MDLinx · 91d ago
- Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches Bloomberg.com · 91d ago
Topics
Related trends
Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health reported Q3 2026 revenue of $401.6 million, up 69% year over year, but narrowed its full-year revenue guidance and cut its adjusted EBITDA forecast, sending shares down sharply.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
6-minute daily habit could help Ozempic users preserve muscle, expert says
Recent coverage examines health trends surrounding GLP-1 medications, detailing new daily habit advice and potential drug risks.
Your job-based insurance cut GLP-1 coverage. Here are some options
Insurers are cutting coverage for GLP-1 weight-loss drugs, with coverage dropping from 57% to 53% between 2025 and 2026, while list prices range from $500 to over $1,000 monthly.
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.